Dr. Usman's Cardiology Notes

  Echo Evaluation of PS and PR Pulmonary valve disease is commonly encountered in congenital and adult cardiology practice. Echocardiography remains the primary tool for diagnosis, severity assessment, and follow-up of Pulmonary Stenosis (PS) and Pulmonary Regurgitation (PR). A systematic echocardiographic approach helps determine valve morphology, hemodynamic severity, and the impact on right ventricular function. --- INTRODUCTION Pulmonary valve pathology may occur as isolated congenital disease, after surgical repair of congenital heart defects, or secondary to pulmonary hypertension and endocarditis. Echocardiography provides comprehensive evaluation through: • Valve morphology • Doppler hemodynamics • Right ventricular size and function • Associated congenital abnormalities Both PS and PR primarily affect the right heart, making careful right-sided assessment essential. --- ECHOCARDIOGRAPHIC VIEWS FOR PULMONARY VALVE The pulmonary valve can be visualized in several standard ec...

  Pharmacologic Therapy for Acute Aortic Dissection --- Introduction Acute Aortic Dissection is a life-threatening cardiovascular emergency caused by a tear in the intimal layer of the aorta, allowing blood to enter the medial layer and create a false lumen. Rapid reduction of aortic wall stress is the cornerstone of initial management. Pharmacologic therapy aims to reduce aortic shear stress, control blood pressure, and limit propagation of the dissection until definitive management such as surgery or endovascular repair is performed. Guideline-directed therapy is primarily based on recommendations from the American Heart Association and European Society of Cardiology. --- Hemodynamic Goals The primary goal is to decrease aortic wall stress (dP/dt) by controlling both heart rate and blood pressure. Target parameters: • Heart rate: < 60 beats/min • Systolic BP: 100–120 mmHg (if tolerated) • Adequate organ perfusion must be maintained Reducing heart rate before aggressive blood p...

 PRIMARY MITRAL REGURGITATION MANAGEMENT Clinical Guide for Physicians --- WHAT IS PRIMARY MITRAL REGURGITATION? Primary Mitral Regurgitation (MR) occurs when the mitral valve apparatus itself is structurally abnormal, leading to backflow of blood from the left ventricle to the left atrium during systole. Common causes include: • Mitral valve prolapse • Degenerative mitral valve disease • Flail leaflet due to chordae rupture • Rheumatic disease • Infective endocarditis • Congenital cleft mitral valve The severity of regurgitation determines management strategy. --- CLASSIFICATION Primary MR is classified based on severity and symptoms. Mild MR Small regurgitant jet with no hemodynamic impact. Moderate MR Larger jet but without significant LV remodeling. Severe MR Characterized by: • Regurgitant volume ≥ 60 ml • Regurgitant fraction ≥ 50% • Effective regurgitant orifice area (EROA) ≥ 0.40 cm² --- CLINICAL PRESENTATION Patients may present with: • Dyspnea on exertion • Fatigue • Palp...

 NSTEMI Timing and Management --- Introduction Non–ST Elevation Myocardial Infarction (NSTEMI) is a common form of Acute Coronary Syndrome (ACS) characterized by myocardial necrosis without persistent ST-segment elevation on ECG. It results from partial or transient occlusion of a coronary artery and requires rapid risk stratification and timely management to prevent progression to larger infarction or death. Early recognition and appropriate timing of invasive management are critical components of modern NSTEMI care. --- Pathophysiology NSTEMI usually occurs due to rupture or erosion of an atherosclerotic plaque followed by platelet aggregation and thrombus formation. Unlike STEMI, the occlusion is often incomplete or intermittent, leading to subendocardial ischemia rather than full-thickness myocardial infarction. Key mechanisms include: • Plaque rupture with non-occlusive thrombus • Severe coronary artery stenosis • Coronary vasospasm • Supply–demand mismatch in vulnerable myoca...

  POST-MI COMPLICATIONS 4 MAJOR COMPLICATIONS EVERY CLINICIAN SHOULD KNOW ──────────────────────── INTRODUCTION Acute myocardial infarction (MI) initiates a cascade of myocardial necrosis, inflammation, and ventricular remodeling. Despite advances in reperfusion therapy, several life-threatening complications can develop in the hours to weeks following infarction. Early recognition of these complications is critical because they significantly increase morbidity and mortality. Four major post-MI complications clinicians must always consider are: • Papillary muscle rupture • Ventricular septal rupture • Free wall rupture • Ventricular aneurysm Understanding their timing, clinical features, and management can be lifesaving. ──────────────────────── 1. PAPILLARY MUSCLE RUPTURE Timing Typically occurs 2–7 days after MI. Pathophysiology Papillary muscles support the mitral valve. When infarction involves the papillary muscle—most commonly the posteromedial papillary muscle due to its sin...

 Assessment of Aortic Stenosis --- Introduction Aortic stenosis (AS) is the most common valvular heart disease requiring intervention in adults. It results from progressive narrowing of the aortic valve opening, leading to obstruction of left ventricular outflow. This increases left ventricular pressure, causes compensatory hypertrophy, and eventually results in heart failure, syncope, or sudden cardiac death if untreated. Accurate assessment of aortic stenosis is essential for determining disease severity, timing of intervention, and prognosis. Echocardiography remains the cornerstone of evaluation, supported by clinical assessment and additional imaging when required. --- Etiology of Aortic Stenosis The major causes include: Degenerative (Calcific) Aortic Stenosis Most common cause in elderly patients due to progressive calcification of the valve. Bicuspid Aortic Valve Congenital abnormality leading to earlier valve degeneration. Rheumatic Heart Disease Leads to leaflet thickenin...

Dual Antiplatelet Therapy (DAPT) Strategies in Acute Coronary Syndrome AHA/ACC Guideline-Based Approach for the First 12 Months Acute coronary syndrome (ACS) includes ST-elevation myocardial infarction (STEMI), non-ST elevation myocardial infarction (NSTEMI), and unstable angina. Platelet activation and thrombosis play a central role in these conditions. Because of this, dual antiplatelet therapy (DAPT) — the combination of aspirin plus a P2Y12 inhibitor — is a cornerstone of treatment. According to AHA/ACC guidelines, DAPT is recommended for 12 months in most patients with ACS, regardless of whether the patient is treated with medical therapy, PCI, or CABG, unless the risk of bleeding outweighs the ischemic benefit. --- What is Dual Antiplatelet Therapy? DAPT consists of: 1. Aspirin 2. A P2Y12 receptor inhibitor The goal is to inhibit platelet aggregation through two different pathways, reducing the risk of: Stent thrombosis Recurrent myocardial infarction Cardiovascular death --- Rec...